195 related articles for article (PubMed ID: 3055701)
21. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
22. Expression of CAR-3 and TAG-72 macromolecules in normal and transformed endometrium: potential diagnostic application in postmenopausal patients.
Bartolazzi A; Mottolese M; Vocaturo A; Bigotti A; Vocaturo G; Atlante G; Prat M; Natali PG
Cancer Res; 1991 Jun; 51(11):3001-5. PubMed ID: 2032237
[TBL] [Abstract][Full Text] [Related]
23. Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3.
Sheer DG; Schlom J; Cooper HL
Cancer Res; 1988 Dec; 48(23):6811-8. PubMed ID: 3180090
[TBL] [Abstract][Full Text] [Related]
24. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011
[TBL] [Abstract][Full Text] [Related]
25. Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas.
Friedman EL; Hayes DF; Kufe DW
Cancer Res; 1986 Oct; 46(10):5189-94. PubMed ID: 3530435
[TBL] [Abstract][Full Text] [Related]
26. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
27. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
Colcher D; Esteban J; Carrasquillo JA; Sugarbaker P; Reynolds JC; Bryant G; Larson SM; Schlom J
Cancer Res; 1987 Aug; 47(15):4218-24. PubMed ID: 3607761
[TBL] [Abstract][Full Text] [Related]
28. Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and MAb B72.3: comparison of in vivo gamma probe counts with in vitro MAb radiolocalization.
Tuttle SE; Jewell SD; Mojzisik CM; Hinkle GH; Colcher D; Schlom J; Martin EW
Int J Cancer; 1988 Sep; 42(3):352-8. PubMed ID: 3417363
[TBL] [Abstract][Full Text] [Related]
29. Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.
Horan Hand P; Colcher D; Salomon D; Ridge J; Noguchi P; Schlom J
Cancer Res; 1985 Feb; 45(2):833-40. PubMed ID: 3881173
[TBL] [Abstract][Full Text] [Related]
30. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions.
Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J
Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527
[TBL] [Abstract][Full Text] [Related]
31. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Meredith RF; Khazaeli MB; Grizzle WE; Orr RA; Plott G; Urist MM; Liu T; Russell CD; Wheeler RH; Schlom J
Hum Antibodies Hybridomas; 1993 Oct; 4(4):190-7. PubMed ID: 8257773
[TBL] [Abstract][Full Text] [Related]
32. Applications of immunocytochemistry to clinical cytology.
Johnston WW; Szpak CA; Thor A; Simpson JF; Schlom J
Cancer Invest; 1987; 5(6):593-611. PubMed ID: 3327572
[TBL] [Abstract][Full Text] [Related]
33. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.
Esteban JM; Colcher D; Sugarbaker P; Carrasquillo JA; Bryant G; Thor A; Reynolds JC; Larson SM; Schlom J
Int J Cancer; 1987 Jan; 39(1):50-9. PubMed ID: 3793270
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma.
Ness MJ; Pour PM; Tempero MA; Linder J
Mod Pathol; 1988 Jul; 1(4):279-83. PubMed ID: 2467286
[TBL] [Abstract][Full Text] [Related]
35. Mammary cancer antigen recognized by monoclonal antibody B72.3 in apocrine metaplasia of the human breast.
Castagna M; Nuti M; Squartini F
Cancer Res; 1987 Feb; 47(3):902-6. PubMed ID: 3542197
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of immunoreactivity of normal tissues from dogs, using monoclonal antibody B72.3.
Clemo FA; DeNicola DB; Zimmermann JL
Am J Vet Res; 1994 Aug; 55(8):1139-47. PubMed ID: 7978655
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
Honma N; Takubo K; Arai T; Younes M; Kasumi F; Akiyama F; Sakamoto G
APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
[TBL] [Abstract][Full Text] [Related]
38. In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72.
Colcher D; Milenic DE; Ferroni P; Roselli M; Schlom J
Int J Rad Appl Instrum B; 1991; 18(4):395-401. PubMed ID: 1864728
[TBL] [Abstract][Full Text] [Related]
39. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
40. Breast carcinoma detection with a combination of radiolabeled monoclonal antibodies. Promising results from immunohistochemistry studies.
Mangili F; Sassi I; Di Rocco M; Leone BE; Garancini P; Santambrogio G
Cancer; 1996 Dec; 78(11):2334-9. PubMed ID: 8941003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
